Printer Friendly

IMPAX and Teva Announce Strategic Alliance for Generic Controlled Release Products.

Health/Medical Writers

HAYWARD, Calif. and JERUSALEM--(BW HealthWire)--June 27, 2001

IMPAX Laboratories, Inc. (Nasdaq:IPXL) and Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) today announced that IMPAX and a subsidiary of Teva have entered into a strategic alliance agreement for twelve controlled release generic pharmaceutical products.

UBS Warburg LLC acted as an advisor to IMPAX in this transaction.

The agreement grants Teva exclusive U.S. marketing rights and an option to acquire exclusive marketing rights in the rest of North America, South America, the European Union, and Israel for the following:
-- Five IMPAX products currently pending approval at the U.S. Food and Drug
Administration (FDA);

-- An option to acquire exclusive marketing rights to one other IMPAX product
currently pending approval at the FDA;

-- Three products currently under development; and

-- Three additional products to be mutually agreed upon.

As part of the transaction, IMPAX will receive up to $22 million through attainment of certain milestones. As an additional sign of its confidence in IMPAX, Teva will invest $15 million in the equity of IMPAX to be made according to a fixed schedule through June 2002.

"This strategic alliance with Teva is a milestone event for IMPAX and is a strong affirmation of our development capabilities and the talents of our drug delivery development team," stated Barry R. Edwards, IMPAX's Co-Chief Executive Officer. "Teva is a world-class marketer of generic pharmaceuticals and we are pleased to have the opportunity to take advantage of that strength."

"We are glad about this opportunity to collaborate with IMPAX. We see this agreement as an integral step in our strategy of consistently upgrading and expanding our pipeline and making high value technology based products available to our customers and to consumers," said William Fletcher, President and CEO of Teva North America.

IMPAX Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and niche generics in addition to the development of branded products. IMPAX markets its generic products through its Global Pharmaceuticals division and intends to market its branded products through the IMPAX Pharmaceuticals division. IMPAX Laboratories is headquartered in Hayward, California, and has a full range of capabilities in its Hayward and Philadelphia facilities.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 40 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. Over 85% of Teva's sales are outside Israel, mainly in North America and Europe. The Company develops, manufactures and markets generic and branded pharmaceuticals and active pharmaceutical ingredients.

"Safe Harbor" statement under the Private Securities Litigation Reform Act

To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA filings and approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, uncertainty of patent litigation filed against us, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.

Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the beliefs and expectations of management. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks and uncertainties that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include the impact of pharmaceutical industry regulation, the difficulty of predicting FDA and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, acceptance and demand for new pharmaceutical products and new therapies, the impact of competitive products and pricing, the availability and pricing of ingredients used in the manufacture of pharmaceutical products, uncertainties regarding market acceptance of innovative products newly launched, currently being sold or in development, the impact of restructuring of clients, reliance on a strategy of acquiring companies and on strategic alliances, exposure to product liability claims, dependence on patent and other protections for our innovative products, fluctuations in currency, exchange and interest rates, operating results, and other factors that are discussed in the Company's Annual Report on Form 20-F and the Company's other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
COPYRIGHT 2001 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Jun 27, 2001
Previous Article:IMPAX Completes $17.5 Million Financing.
Next Article:Spectrum Oil Forms Subsidiary to Make Oil and Gas Land Acquisition. Financing Agreements Signed and Completed for Spindletop Energy L.L.C.

Related Articles
IMPAX Names David S. Doll Senior Vice President, Sales and Marketing.
Teva Reports a 41% Increase in Second Quarter Net Income On an Increase in Sales of 16%; EPS Reached $0.47, Up 38%.
IMPAX Receives $3.75 Million Investment From Teva Pharmaceutical.
IMPAX Receives $3.75 Million Investment from Teva Pharmaceutical.
IMPAX Reports Fourth Quarter Financial Results; Two ANDAs Filed with FDA in Quarter for a Total of Eight in 2001; Expects to File 6 to 8 ANDAs in...
IMPAX Comments on Claritin Announcement by Schering-Plough; Also Announces Alliance With Novartis Consumer Health, Inc. for an OTC Loratadine Product.
IMPAX Receives $3.75 Million Investment From Teva Pharmaceutical.
IMPAX Reports First Quarter Financial Results; Quarter Highlights Include FDA Approval and Tentative Approval of ANDAs and Higher Revenues.
IMPAX Receives $3.75 Million Investment From Teva Pharmaceutical.
IMPAX Receives Final FDA Approval for Generic Ditropan(R) XL 5 mg and 10 mg.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters